Business Context and Reporting Period
Company: Imprimis Pharmaceuticals, Inc. (Note: Metadata referenced "Harrow, Inc." but the filing text identifies Imprimis Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2017
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement).
Key Financial Metrics and Transaction Details
This filing reports a specific asset sale transaction rather than standard periodic financial results (revenue, profit, cash flow, or margins). Key transaction metrics include:
- Total Purchase Price: Approximately $450,000.
- Upfront Cash Payment: $40,000 payable at closing.
- Deferred Payment (Seller's Note): $410,000 principal bearing 6% annual interest.
- Payment Schedule: 48 monthly payments of $9,628.86 (totaling $462,185.28 with interest).
- Assets Sold: Substantially all assets associated with the sinus-related business, including IP, trademarks, inventory, equipment, customer lists, and the lease obligation for the Pennsylvania pharmacy.
Material Changes and Transaction Conditions
The filing details specific conditions and potential adjustments to the transaction value:
- Early Payoff Option: Buyers may pay a lump sum of $365,000 prior to December 31, 2017, waiving all remaining amounts due.
- Revenue Adjustment: The principal amount of the Seller's Note may be reduced by $125,000 if revenues associated with the assets 60 days post-closing are less than 60% of revenues 60 days pre-closing.
- Closing Date: Expected on or around July 17, 2017, subject to customary terms.
Outlook, Risks, and Management Commentary
Management included a cautionary note regarding forward-looking statements. Key risks identified include:
- Possibility that the transaction closing may be delayed or not occur.
- Difficulties with integration or realizing expected benefits.
- General regulatory developments impacting compounding pharmacies and the pharmaceutical industry.
- The filing does not provide specific guidance on future revenue or profit margins for the remaining business operations.
Investor Verification Checklist
- Verify the actual closing date of the transaction (expected July 17, 2017).
- Confirm whether the revenue threshold for the $125,000 principal reduction is met 60 days post-closing.
- Monitor if the Buyer exercises the early payoff option of $365,000 before December 31, 2017.
- Review subsequent filings for the impact of this asset divestiture on the Company's remaining liquidity and operational focus.